About Francois Beaubien
Francois Beaubien is a director at Apnimed.
Form D filings also name Francois Beaubien as a director at Evommune.
Francois Beaubien first appears on SEC filings in 2023.
Experience
This experience comes from Francois Beaubien's profile and from SEC filings. For roles taken from filings, the years are when the filings name Francois Beaubien in the role, so the role may have started earlier or lasted longer.
ST
Sling Therapeutics Current
Board Member
2026 – Present
SM
Sectoral Asset Management Current
Partner
2014 – Present
Apnimed, Inc.
Director
2022 – 2026 · Cambridge, MA
Develops oral medicines for people with sleep apnea and other sleep-related breathing diseases.
LT
LENZ Therapeutics
Board Observer
2023 – 2024
PT
Pipeline Therapeutics
Board Observer
2020 – 2024
Key Colleagues at Startups
The people Francois Beaubien works with at each company, as listed on that company's latest Form D.
Apnimed, Inc. · Form D, Mar 27, 2026
LM
Lawrence Miller
Executive officer and director
Paul Fonteyne
Director
DM
Dennis Molnar
Executive officer
Barry Wohl
Chief Business Officer
JA
Joseph Avellone
Director
Chris Dimitropoulos
Director
KL
Kevin Lind
Chief Executive Officer and director
IC
Isaac Cheng
Director
GS
Gary Sender
Director
RB
Ramzi Benamar
Chief Financial Officer
Evommune, Inc. · Form D, Jan 8, 2025
JD
Janice Drew
Executive officer
DC
David Cohen
Director
RH
Robert Hopfner
Director
DD
Derek DiRocco
Director
GM
Gregory Moss
Chief Business and Legal Officer
EB
Eugene Bauer
Executive officer and director
FW
Felice Verduyn-van Weegen
Director
JP
Jeegar Patel
Executive officer
YY
Yuexin Yu
Director
BM
Benjamin McGraw
Director
LP
Luis Pena
Executive officer and director
KC
Kyle Carver
Executive officer